29th May, 2019
Further to the disclosure (Ref: DIL:DIL/BSE/2019-20/F.No.: 49) regarding the major maintenance shutdown and de-bottlenecking programme at Dahej facility of the Company’s subsidiary, Fermenta Biotech Ltd., we wish to announce that the maintenance work as well as the de-bottlenecking programme is now complete. The plant had undergone a routine shutdown for repairs and maintenance along with a de-bottlenecking programme for capacity expansion.
With effect from 29th May 2019, the facility is back to operating at full capacities, which have increased by about 15% as a result of the de-bottlenecking programme.
Commenting on the development, Mr. Prashant Nagre, CEO, Fermenta Biotech Limited said :
“ The de-bottlenecking programme was a part of the capacity expansion measures that we are undertaking in order to cater to the increased demand for our products. We are happy to declare that this programme is now complete, and the Dahej facility has commenced production at its elevated capacity. Fermenta has always been committed to delivering quality products to its valued customers, and going forward as well, we will work towards our endeavour for excellence through continuous improvement in all our processes. ”
About DIL Limited :
DIL holds 91.2% equity stake in Fermenta Biotech Limited (FBL), which was incorporated in 1986.
FBL is engaged in manufacturing of Vitamin D3, other specialty APIs, biological enzymes and also offers integrated biotech based environmental solutions.
FBL has 2 manufacturing facilities :
· Kullu in Himachal Pradesh – cGMP certified and currently manufactures Vitamin D3, specialty API’s and Enzymes
· Dahej SEZ – set up in 2011 and manufactures Vitamin D3
DIL has developed premium office spaces named ‘THANE ONE’, with a total leasable area of approximately 200,000 sq. ft., which is 100% occupied.
For more information about the Company and its businesses, please visit our website www.dil.net
Safe Harbor :
Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.
For further details please contact :
Company : DIL Limited
CIN No. : L99999MH1951PLC008485
Name : Mr. Sumesh Gandhi
Designation : Chief Financial Officer
Mob. No. : +91 9833818386
Email id. : sumesh.gandhi@dil.net
Thanks for sharing this great content. It is really informative and useful., You can also check this Similar site cgmp adalah.
ReplyDelete